WO2016159644A1 - 신규 벤조산 아마이드 화합물 - Google Patents
신규 벤조산 아마이드 화합물 Download PDFInfo
- Publication number
- WO2016159644A1 WO2016159644A1 PCT/KR2016/003235 KR2016003235W WO2016159644A1 WO 2016159644 A1 WO2016159644 A1 WO 2016159644A1 KR 2016003235 W KR2016003235 W KR 2016003235W WO 2016159644 A1 WO2016159644 A1 WO 2016159644A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- benzoic acid
- acid amide
- dimethoxy
- dihydroxy
- benzyl
- Prior art date
Links
- 0 COc1c(C2C=CC=CC2)cc2C(NCc(ccc(O)c3)c3O)=*c2c1 Chemical compound COc1c(C2C=CC=CC2)cc2C(NCc(ccc(O)c3)c3O)=*c2c1 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/68—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/70—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a saturated carbon skeleton containing rings
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/48—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Definitions
- the present disclosure relates to novel benzoic acid amide compounds and their use.
- Melanin protects skin organs under the dermis by blocking UV rays in the epidermal layer and protects the skin by absorbing free radicals.
- melanin is a major factor in determining the color of the skin, and when present in excess, it is also a cause of skin pigmentation such as spots, freckles and spots.
- Melanin is made from melanocytes present in the basal layer of the skin, and it is known that the production is promoted by stimulation such as ultraviolet rays or inflammation. Therefore, it is possible to reduce melanin production by reducing external stimulation and blocking signal transduction, or inhibiting the synthesis or activity of melanin-producing enzyme tyrosinase.
- kojic acid, hydroquinone, arbutin, azelaic acid, aloesin, 4-butylresosocinol, resveratrol, ceramide, sphingosine-1-phosphate, sphingosylphosphorylcholine, etc. promote the degradation or glycosylation of tyrosinase. It is known to regulate melanin production by controlling. However, they are not well utilized due to unsatisfactory whitening effects, low stability and skin irritation. Therefore, there is a need for development of a substance having excellent whitening effect and few side effects.
- One aspect of the present invention is to provide a novel benzoic acid amide derivative compound.
- Another aspect of the present invention is to provide a composition comprising a benzoic acid amide derivative compound exhibiting a skin whitening effect.
- One aspect of the present invention includes a structure of Formula 1,
- R 1 is halogen, C 1 to C 5 alkyl, C 3 to C 6 cycloalkyl, C 3 to C 6 cycloalkyl is selected from the alkenyl, the group consisting of C 6 to group C 18 aryl, wherein the aryl group is substituted Unsubstituted or substituted with one or more of halogen, C 1 to C 5 alkyl, C 1 to C 5 alkoxy, methylenedioxy and nitro groups, isomers thereof, pharmaceutically acceptable salts thereof, prodrugs thereof, Hydrates or solvates thereof are provided.
- compositions for skin whitening comprising the compound of Formula 1, an isomer thereof, a pharmaceutically acceptable salt thereof, a prodrug thereof, a hydrate thereof, or a solvate thereof.
- One aspect of the present invention provides a novel compound, an isomer thereof, a pharmaceutically acceptable salt thereof, a prodrug thereof, a hydrate thereof or a solvate thereof, which has a whitening effect.
- compositions comprising a novel compound, an isomer thereof, a pharmaceutically acceptable salt thereof, a prodrug thereof, a hydrate thereof or a solvate thereof according to one aspect of the present invention.
- novel compounds, isomers thereof, pharmaceutically acceptable salts thereof, prodrugs thereof, hydrates thereof or solvates thereof and compositions comprising the same provide the effect of inhibiting melanin production.
- novel compounds, isomers thereof, pharmaceutically acceptable salts thereof, prodrugs thereof, hydrates thereof or solvates thereof and compositions comprising them provide the effect of inhibiting tyrosinase activity. .
- novel compounds, isomers thereof, pharmaceutically acceptable salts thereof, prodrugs thereof, hydrates thereof or solvates thereof and compositions comprising the same provide excellent skin lightening effects.
- skin refers to a tissue covering the body surface of an animal, and is a broad concept including not only tissues covering the body surface such as the face or body, but also the scalp and hair.
- Alkyl as used herein means a monovalent saturated aliphatic hydrocarbon chain.
- the hydrocarbon chain may be straight or branched chain.
- an “alkyl” may have from 1 to 5 carbon atoms (“C 1 to C 5 alkyl”) and in another aspect from 1 to 4 carbon atoms (“C 1 to C 4 alkyl” )
- alkyl includes, but is not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, tert-butyl or t-amyl.
- alkoxy refers to an -OR group, where R refers to an alkyl group as defined above. Specifically “alkoxy” refers to methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy or 1,2-dimethylbutoxy and the like. Including but not limited to.
- cycloalkyl refers to a cyclic saturated aliphatic hydrocarbon group.
- the C numbers are given corresponding to the number of carbon atoms forming the ring and are mentioned with the cycloalkyl group.
- C 3 to C 6 cycloalkyl means cycloalkyl having 3 to 6 ring forming C atoms.
- examples of “cycloalkyl” include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, and the like.
- a "cycloalkyl” group may be substituted with one or more alkyl groups, such as C 1 to C 6 alkyl groups, specifically C 1 to C 4 alkyl groups, more specifically methyl groups. If “cycloalkyl” has one or more substituents, these substituents may be the same or different.
- cycloalkoxy refers to an -OR group, where R refers to a “cycloalkyl” group as defined above.
- halo or halogen includes fluoro, chloro, bromo or iodo.
- the halo group may be fluoro or chloro.
- aryl is meant herein an aromatic hydrocarbon radical.
- aryl groups include phenyl, naphthyl, indenyl, azulenyl or trasene, of which phenyl may be preferred.
- isomers in particular are not only optical isomers (eg, essentially pure enantiomers, essentially pure diastereomers or mixtures thereof), but also form isomers ( conformation isomers (ie, isomers that differ only by their angles of one or more chemical bonds), position isomers (especially tautomers) or geometric isomers (eg, cis-trans isomers) do.
- essentially pure means, when used in connection with, for example, an enantiomer or diastereomer, about 90% or more, specifically about 95% or more, of specific compounds, for example enantiomers or diastereomers, More specifically at least about 97% or at least about 98%, even more specifically at least about 99%, even more specifically at least about 99.5% (w / w).
- pharmaceutically acceptable means the approval of a government or equivalent regulatory body to use in animals, more specifically in humans, by avoiding significant toxic effects when used in conventional medicinal dosages. It can be received or approved, or listed in a pharmacopoeia or recognized as another general pharmacopeia.
- salts means salts according to one aspect of the invention that are pharmaceutically acceptable and have the desired pharmacological activity of the parent compound.
- the salt is formed from (1) an inorganic acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, or the like; Or acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3- (4-hydroxybenzoyl) Benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenes
- prodrug refers to a drug that modulates physical and chemical properties by chemically changing a drug, which itself does not exhibit physiological activity, but is originally produced by the action of a chemical or enzyme in the body after administration. The drug can be turned into a drug.
- hydrate refers to a compound to which water is bound, and is a broad concept including an inclusion compound having no chemical bonding force between water and the compound.
- solvate means a higher order compound produced between molecules or ions of a solute and molecules or ions of a solvent.
- One aspect of the invention includes the structure of Formula 1, in Formula 1
- R 1 is each independently selected from the group consisting of halogen, C 1 to C 4 alkyl, C 3 to C 6 cycloalkyl, C 3 to C 6 cycloalkenyl, an aryl group, and the aryl group is unsubstituted, halogen, C Compounds substituted with one or more of 1 to C 5 alkyl, C 1 to C 5 alkoxy, methylenedioxy and nitro groups, isomers thereof, pharmaceutically acceptable salts thereof, prodrugs thereof, hydrates thereof or solvates thereof to provide.
- One aspect of the present invention is i) a first step of synthesizing a benzoic acid amide compound by reacting a benzoic acid derivative of Formula 2 with an alkylphenylamine substituted with a hydroxy group;
- R is selected from the group consisting of halogen, C 1 to C 5 alkyl, C 3 to C 6 cycloalkyl and C 3 to C 6 cyclo alkenyl
- the product that has passed through the first step may further include the following second step.
- a method for preparing an benzoic acid amide compound substituted with an alkyl or aryl group comprising a second step of reacting the resulting bromo benzoic acid amide derivative with a suitable aryl boronic acid under a palladium catalyst to synthesize a benzoic acid amide compound in biaryl form; .
- a method for preparing an benzoic acid amide compound substituted with an alkyl or aryl group may be represented by Scheme 1 below.
- R is selected from the group consisting of halogen, C 1 to C 5 alkyl, C 3 to C 6 cycloalkyl, C 3 to C 6 cycloalkenyl, aryl group, wherein the aryl group is unsubstituted or halogen, C 1 to C 5 Alkyl, C 1 to C 5 alkoxy, methylenedioxy, a compound substituted with a nitro group, an isomer thereof, a pharmaceutically acceptable salt thereof, a prodrug thereof, a hydrate thereof or a solvate thereof,
- a method for preparing a benzoic acid amide compound includes: i) synthesizing a benzoic acid amide compound by reacting an alkyl (or bromo) benzoic acid derivative with an alkylphenylamine substituted with a hydroxy group; And
- Method for producing a benzoic acid amide compound according to another aspect of the present invention is i) N-hydroxysuccinimide (HOSu), N, N'- dicyclohexylcarbodiimide (DCC) in the presence of alkyl (or bromo ) Reacting the benzoic acid derivative with an alkylphenylamine substituted with a hydroxy group to synthesize a benzoic acid amide compound; And
- compositions for skin whitening comprising the compound, an isomer thereof, a pharmaceutically acceptable salt thereof, a prodrug thereof, a hydrate thereof, or a solvate thereof as an active ingredient.
- One aspect of the present invention is a method for enhancing skin whitening of a subject, which method requires an effective amount of the compound, an isomer thereof, a pharmaceutically acceptable salt thereof, a prodrug thereof, a hydrate thereof, or a solvate thereof. It provides a method comprising the step of administering to a subject.
- One aspect of the present invention provides the use of the above compounds, isomers thereof, pharmaceutically acceptable salts thereof, prodrugs thereof, hydrates thereof or solvates thereof in preparing compositions for enhancing skin lightening.
- One aspect of the present invention provides the above compound, isomer thereof, pharmaceutically acceptable salt thereof, prodrug thereof, hydrate thereof or solvate thereof for enhancing skin whitening.
- the compounds, isomers thereof, pharmaceutically acceptable salts thereof, prodrugs thereof, hydrates thereof or solvates thereof may inhibit melanogenesis or inhibit the activity of tyrosinase, thereby exhibiting excellent skin lightening effects.
- compositions according to one aspect of the invention may comprise from 0.01% to 20% by weight of said compound, isomer thereof, pharmaceutically acceptable salt thereof, prodrug thereof, hydrate thereof or solvate thereof, based on the total weight of the composition.
- the compound, isomer thereof, pharmaceutically acceptable salt thereof, prodrug, hydrate thereof or solvate thereof may be at least 0.01%, at least 0.02%, at least 0.03%, at least 0.04, based on the total weight of the composition.
- the compound, isomer thereof, pharmaceutically acceptable salt thereof, prodrug, hydrate thereof or solvate thereof may be at most 20%, at most 19.5%, at most 19%, 18 based on the total weight of the composition.
- the compound, the isomer thereof, the pharmaceutically acceptable salt thereof, the prodrug thereof, the hydrate thereof, or the solvate thereof are less than 0.01% by weight, a sufficient skin lightening effect may not be obtained, and when it exceeds 20% by weight, The effect is low and may not be desirable.
- One aspect of the present invention provides a composition for external application for skin comprising the compound, an isomer thereof, a pharmaceutically acceptable salt thereof, a prodrug thereof, a hydrate thereof, or a solvate thereof as an active ingredient.
- Another aspect of the present invention provides a cosmetic composition comprising the compound, isomer thereof, pharmaceutically acceptable salt thereof, prodrug thereof, hydrate thereof or solvate thereof as an active ingredient.
- the cosmetic composition may exhibit an excellent skin whitening effect, specifically, it can improve or prevent blemishes, freckles, spots, skin pigmentation.
- Cosmetic compositions according to the invention may be provided in all formulations suitable for topical application.
- it may be provided in the form of a solution, an emulsion obtained by dispersing an oil phase in an aqueous phase, an emulsion obtained by dispersing an aqueous phase in an oil phase, a suspension, a solid, a gel, a powder, a paste, a foam, or an aerosol composition.
- Compositions of such formulations may be prepared according to conventional methods in the art.
- the cosmetic composition according to the present invention may include other ingredients in addition to the above-mentioned substances within the range not impairing the main effect, preferably giving a synergistic effect to the main effect.
- arbutin and ascorbic acid derivatives may further include a skin whitening effect of the cosmetic composition according to the present invention.
- the cosmetic composition according to the present invention may further include a moisturizer, an emulsifier, a surfactant, a ultraviolet absorber, a preservative, a bactericide, an antioxidant, a pH adjuster, organic and inorganic pigments, flavors, coolants, or limiting agents. have.
- the blending amount of the above components can be easily selected by those skilled in the art within the range that does not impair the object and effect of the present invention, the blending amount may be 0.01 to 5% by weight, specifically 0.01 to 3% by weight based on the total weight of the composition. have.
- One aspect of the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising the compound, an isomer thereof, a pharmaceutically acceptable salt thereof, a prodrug thereof, a hydrate thereof, or a solvate thereof as an active ingredient.
- the pharmaceutical composition may exhibit an excellent skin whitening effect, and specifically may improve or treat blemishes, freckles, moles, and skin pigmentation.
- compositions according to one aspect of the present invention may be administered orally, parenteral, rectal, topical, transdermal, intravenous, intramuscular, intraperitoneal, subcutaneous.
- Formulations for oral administration may be tablets, pills, soft and hard capsules, granules, powders, granules, solutions, emulsions or pellets, but are not limited thereto. It is not.
- Formulations for parenteral administration may be, but are not limited to, solutions, suspensions, emulsions, gels, injections, drops, suppositories, patches or sprays.
- the formulations can be readily prepared according to conventional methods in the art and include surfactants, excipients, hydrating agents, emulsifiers, suspending agents, salts or buffers for controlling osmotic pressure, colorants, spices, stabilizers, preservatives, preservatives or Other commercially available auxiliaries can be used as appropriate.
- the active ingredient of the pharmaceutical composition according to one aspect of the present invention will vary depending on the age, sex, weight, pathology and severity of the subject to be administered, the route of administration or the judgment of the prescriber. Dosage determination based on these factors is within the level of one skilled in the art and its daily dosage may be, for example, from 0.1 mg / kg / day to 100 mg / kg / day, more specifically from 5 mg / kg / day to 50 mg / kg. May be, but is not limited to.
- One aspect of the present invention provides a composition for external application for skin comprising the compound, an isomer thereof, a pharmaceutically acceptable salt thereof, a prodrug thereof, a hydrate thereof, or a solvate thereof as an active ingredient.
- Another aspect of the present invention provides a food composition comprising the compound, an isomer thereof, a pharmaceutically acceptable salt thereof, a prodrug thereof, a hydrate thereof, or a solvate thereof as an active ingredient.
- the food composition may be a health food composition.
- the formulation of the food composition according to the present disclosure is not particularly limited, but may be, for example, formulated as a tablet, granule, powder, liquid such as drink, caramel, gel, bar, or the like.
- the food composition of each formulation may be suitably selected by a person skilled in the art according to the formulation or purpose of use in addition to the active ingredient, and may be synergistic when applied simultaneously with other raw materials.
- the dosage determination of the active ingredient is within the level of those skilled in the art, and the daily dosage thereof may be, for example, 0.1 mg / kg / day to 5000 mg / kg / day, more specifically 1 It may be mg / kg / day to 500 mg / kg / day, but is not limited thereto, and may vary depending on various factors such as age, health condition, complications of the subject to be administered.
- the food composition according to the present disclosure may be, for example, various functional foods such as chewing gum, caramel products, candy, ice cream, confectionery, beverage products such as soft drinks, mineral water, alcoholic drinks, vitamins and minerals, and the like. Can be.
- the food composition which is an aspect of the present invention, includes various nutrients, vitamins, minerals (electrolytes), synthetic flavors such as synthetic and natural flavors, colorants and enhancers (such as cheese and chocolate), pectic acid and salts thereof, Alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like.
- the functional food compositions of the present invention may include a natural fruit juice and a pulp for the production of fruit juice beverages and vegetable beverages. These components can be used independently or in combination. The proportion of such additives is not so critical but is typically included in the range of 0 to about 20 parts by weight per 100 parts by weight of the composition of the present invention.
- Example 11 5-cyclohexen-1-yl-N- (2,4-dihydroxy-benzyl) -2,4-dimethoxy-benzoic acid amide (0.1 g) obtained in Example 11 was prepared by ethanol (10 ml). After dissolving, 5% palladium-activated carbon catalyst was added thereto, followed by reduction for 4 hours under hydrogen atmosphere. The reaction mixture was filtered through celite and concentrated under reduced pressure to give the title compound (0.09 g) as a white solid.
- the effect of inhibiting melanogenesis in melanocyte-producing cells of the benzoic acid amide derivative compound prepared in the above example was measured by Dooley's method.
- DMEM (Cat No. 11995), FBS (Cat No. 16000-044) and antibiotic-antifungal reagents (Cat No. 15240-062) required for cell culture were purchased from Invitrogen (GIBCO). Cell lines were incubated under conditions of 37 ° C., 5% CO 2 .
- Example 10 was replaced with a medium containing 10 ppm.
- rucinol Tokyo Chemical Industry (Japan, Cat. No. B3773) showing an excellent whitening material was used.
- 1N NaOH was treated and reacted at 60 ° C. for 2 hours to melt melanin contained in the cells, and the amount of melanin was measured by measuring absorbance at 405 nm. From this the concentration of Example (IC 50 ) required to reduce melanin production in melanocytes by half is calculated and shown in the table below.
- the compounds of the Examples show excellent melanin production inhibitory ability, such as rucinol. Therefore, it can be seen that the benzoic acid derivative compounds according to the present invention have excellent skin whitening effect by inhibiting melanin production.
- the inhibitory effect of mushroom tyrosinase activity of the benzoic acid amide derivative compound was measured by Vanni et al. Specifically, 49.5 ⁇ l of 0.1 M potassium phosphate buffer (pH 6.8), 45 ⁇ l of distilled water (DW), 0.5 ⁇ l (10 units) of mushroom tyrosinase (SIGMAT-7755), and 5 ⁇ l of Example 0.3 mg / 50 ⁇ l of aqueous solution of tyrosine mL was mixed in a 96-culture vessel (150 ⁇ l total) and enzymatically reacted at 37 ° C for 10 minutes.
- 5-adamantan-1-yl-N- (2,4-dihydroxybenzyl) -2,4-dimethoxy-benzoic acidamide were used as a positive control.
- 5-adamantan-1-yl-N- (2,4-dihydroxybenzyl) -2,4-dimethoxy-benzoic acid amide is a substance synthesized by the present inventors, and is described in patent document US20140234241A1.
- Example 1 0.19 ⁇ M
- Example 2 0.15 ⁇ M
- Example 3 0.18 ⁇ M
- Example 4 0.07 ⁇ M
- Example 5 0.06 ⁇ M
- Example 6 0.06 ⁇ M
- Example 7 0.07 ⁇ M
- Example 9 0.06 ⁇ M
- Example 10 0.07 ⁇ M
- Example 11 0.12 ⁇ M
- Example 12 0.12 ⁇ M
- the benzoic acid amide derivatives of the examples are excellent in inhibiting the activity of mushroom tyrosinase, the effect is equivalent to or more than the commercial whitening agent Lucisin, the inhibitory activity of the previous study 5-adaman It shows superior tyrosinase inhibitory activity compared to the benzoic acid derivatives having a substituted tilyl group (US20140234241A1). Therefore, it can be seen that the benzoic acid amide derivative compounds according to the present invention have an excellent skin whitening effect by inhibiting the activity of tyrosinase.
- the lotion is prepared according to a conventional method with the composition described in the table below.
- a nutritive cream is prepared according to a conventional method with the composition described in the table below.
- Example 2.0 Polysorbate 60 1.5 Solbitan Sesquioleate 0.5 PEG 60 Cured Castor Oil 2.0 Liquid paraffin 10.0 Squalane 5.0 Caprylic / Caprol Triglycerides 5.0 glycerin 5.0 Butylene glycol 3.0 Propylene glycol 3.0 Triethanolamine 0.2 Preservative, coloring, flavoring Quantity Purified water Remaining amount
- Massage cream is prepared according to a conventional method with the composition described in the table below.
- Gels are prepared according to conventional methods with the compositions described in the table below.
- Ointments were prepared by conventional methods in the compositions described in the table below.
- Example 1.5 glycerin 8.0 Butylene glycol 4.0 Liquid paraffin 15.0 Beta Glucan 7.0 Carbomer 0.1 Caprylic / Capric Triglycerides 3.0 Squalane 1.0 Cetearyl Glucoside 1.5 Sorbitan stearate 0.4 Cetearyl Alcohol 1.0 Beeswax 4.0 Preservative, coloring, flavoring Quantity Purified water Remaining amount
- Vitamin B12 ......... 0.2 ⁇ g
- Nicotinic Acid Amide ... 1.7 mg
- composition ratio of the said vitamin and mineral mixture was mixed and consisted the component suitable for a healthy food in a preferable formulation example, you may change arbitrarily the compounding ratio.
- the above ingredients are mixed according to a conventional method for preparing a health beverage, then stirred and heated at 85 ° C. for about 1 hour, and then the resulting solution is filtered and sterilized.
- Example 100 mg, soybean extract 50 mg, glucose 100 mg, red ginseng extract 50 mg, starch 96 mg and magnesium stearate 4 mg were mixed and 30 mg ethanol was added to form granules, followed by drying at 60 ° C. Tableting using a tableting machine.
- Example 100 mg, soybean extract 50 mg, glucose 100 mg, and starch 600 mg were mixed and 100 mg of 30% ethanol was added to form granules, followed by drying at 60 ° C. to form granules and then filling into fabrics.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Cosmetics (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Description
시험 물질 | IC50 |
루시놀 | IC50 = 0.8 μM |
실시예 1 | IC50 = 2.3 μM |
실시예 5 | IC50 = 0.7 μM |
실시예 6 | IC50 = 0.7 μM |
실시예 7 | IC50 = 0.7 μM |
실시예 8 | IC50 = 1.5 μM |
실시예 9 | IC50 = 0.6 μM |
실시예 10 | IC50 = 1.3 μM |
실시예 11 | IC50 = 0.9 μM |
실시예 12 | IC50 = 2.1 μM |
시험 물질 | IC50 |
루시놀 | 0.06 μM |
5-아다만탄-1-일-N-(2,4-디히드록시벤질)-2,4-다이메톡시- 벤조산아미드 | 0.31 μM |
실시예 1 | 0.19 μM |
실시예 2 | 0.15 μM |
실시예 3 | 0.18 μM |
실시예 4 | 0.07 μM |
실시예 5 | 0.06 μM |
실시예 6 | 0.06 μM |
실시예 7 | 0.07 μM |
실시예 8 | 0.05 μM |
실시예 9 | 0.06 μM |
실시예 10 | 0.07 μM |
실시예 11 | 0.12 μM |
실시예 12 | 0.12 μM |
성분 | 함량(중량%) |
실시예 | 0.1 |
글리세린 | 3.0 |
부틸렌글리콜 | 2.0 |
프로필렌글리콜 | 2.0 |
카르복시비닐폴리머 | 0.1 |
PEG 12 노닐페닐에테르 | 0.2 |
폴리솔베이트 80 | 0.4 |
에탄올 | 10.0 |
트리에탄올아민 | 0.1 |
방부제, 색소, 향료 | 적량 |
정제수 | 잔량 |
성분 | 함량(중량%) |
실시예 | 2.0 |
폴리솔베이트 60 | 1.5 |
솔비탄세스퀴올리에이트 | 0.5 |
PEG 60 경화피마자유 | 2.0 |
유동파라핀 | 10.0 |
스쿠알란 | 5.0 |
카프릴릭/카프락트리글리세라이드 | 5.0 |
글리세린 | 5.0 |
부틸렌글리콜 | 3.0 |
프로필렌글리콜 | 3.0 |
트리에탄올아민 | 0.2 |
방부제, 색소, 향료 | 적량 |
정제수 | 잔량 |
성분 | 함량(중량%) |
실시예 | 1.0 |
밀납 | 10.0 |
폴리솔베이트 60 | 1.5 |
PEG 60 경화피마자유 | 2.0 |
솔비탄세스퀴올레이트 | 0.8 |
유동파라핀 | 40.0 |
스쿠알란 | 5.0 |
카프릴릭/카프릭트리글리세라이드 | 4.0 |
글리세린 | 5.0 |
부틸렌글리콜 | 3.0 |
프로필렌글리콜 | 3.0 |
트리에탄올아민 | 0.2 |
방부제, 색소, 향료 | 적량 |
정제수 | 잔량 |
성분 | 함량(중량%) |
실시예 | 0.2 |
폴리비닐알콜 | 13.0 |
소듐카르복시메틸셀룰로오스 | 0.2 |
글리세린 | 5.0 |
알란토인 | 0.1 |
에탄올 | 6.0 |
PEG 12 노닐페닐에테르 | 0.3 |
폴리솔베이트 60 | 0.3 |
방부제, 색소, 향료 | 적량 |
정제수 | 잔량 |
성분 | 함량(중량%) |
실시예 | 0.5 |
에틸렌디아민초산나트륨 | 0.05 |
글리세린 | 5.0 |
카르복시비닐폴리머 | 0.3 |
에탄올 | 5.0 |
PEG 60 경화피마자유 | 0.5 |
트리에탄올아민 | 0.3 |
방부제, 색소, 향료 | 적량 |
정제수 | 잔량 |
성분 | 함량(중량%) |
실시예 | 1.5 |
글리세린 | 8.0 |
부틸렌글리콜 | 4.0 |
유동파라핀 | 15.0 |
베타글루칸 | 7.0 |
카보머 | 0.1 |
카프릴릭/카프릭 트리글리세라이드 | 3.0 |
스쿠알란 | 1.0 |
세테아릴 글루코사이드 | 1.5 |
소르비탄 스테아레이트 | 0.4 |
세테아릴 알코올 | 1.0 |
밀납 | 4.0 |
방부제, 색소, 향료 | 적량 |
정제수 | 잔량 |
Claims (15)
- 제 1 항에 있어서,상기 화합물은N-(2,4-다이하이드록시-벤질)-2,4-다이메톡시-5-메틸-벤조산아마이드,5-브로모-N-(2,4-다이하이드록시-벤질)-2,4-다이메톡시-벤조산아마이드,5-tert-부틸-N-(2,4-다이하이드록시-벤질)-2,4-다이메톡시-벤조산아마이드,N-(2,4-다이하이드록시-벤질)-2,4-다이메톡시-5-페닐-벤조산아마이드,N-(2,4-다이하이드록시-벤질)-2,4-다이메톡시-5-(4-플루오로-페닐)-벤조산아마이드,N-(2,4-다이하이드록시-벤질)-2,4-다이메톡시-5-(4-메톡시-페닐)-벤조산아마이드,5-벤조[1,3]다이옥솔-5-일-N-(2,4-다이하이드록시-벤질)-2,4-다이메톡시-벤조산아마이드,5-사이클로헥센-1-일-N-(2,4-다이하이드록시-벤질)-2,4-다이메톡시-벤조산아마이드,N-(2,4-다이하이드록시-벤질)-2,4-다이메톡시-5-(3,5-다이메틸-페닐)-벤조산아마이드,5-사이클로헥실-N-(2,4-다이하이드록시-벤질)-2,4-다이메톡시-벤조산아마이드,N-(2,4-다이하이드록시-벤질)-2,4-다이메톡시-5-(3,4-다이플루오로-페닐)-벤조산아마이드 및N-(2,4-다이하이드록시-벤질)-2,4-다이메톡시-5-(3-나이트로-페닐)-벤조산아마이드로 이루어진 그룹에서 선택된 것인 화합물, 이의 이성질체, 이의 약학적으로 허용 가능한 염, 이의 프로드럭, 이의 수화물 또는 이의 용매화물.
- 제 1 항에 있어서,상기 화합물은 N-(2,4-다이하이드록시-벤질)-2,4-다이메톡시-5-(3,5-다이메틸-페닐)-벤조산아마이드인 것인 화합물, 이의 이성질체, 이의 약학적으로 허용 가능한 염, 이의 프로드럭, 이의 수화물 또는 이의 용매화물.
- 제 1항 내지 제 3항에 따른 화학식 1의 화합물, 이의 이성질체, 이의 약학적으로 허용 가능한 염, 이의 프로드럭, 이의 수화물 또는 이의 용매화물의 제조방법으로서,반응물로 하기 화학식 2의 벤조산 유도체;와 하이드록시기가 치환된 알킬페닐아민;을 반응시키는 제 1단계를 포함하는 하기 화학식 1 화합물의 제조방법:[화학식 1]상기 화학식 1에서R1 은 할로겐, C1 내지 C5 알킬, C3 내지 C6 시클로알킬, C3 내지 C6 시클로 알케닐, C6 내지 C18 아릴기로 이루어진 그룹에서 선택되고, 상기 아릴기는 치환되지 않거나, 할로겐, C1 내지 C5 알킬, C1 내지 C5 알콕시, 메틸렌다이옥시 및 니트로기 중 하나 이상으로 치환된 것임;[화학식 2]R 은 할로겐, C1 내지 C5 알킬, C3 내지 C6 시클로알킬 및 C3 내지 C6 시클로 알케닐로 이루어진 그룹에서 선택된 것임.
- 제 4항에 있어서,상기 화학식 2의 화합물은 R이 할로겐인 화학식 1 화합물의 제조방법.
- 제 5항에 있어서,상기 화학식 2의 R이 브롬기인 브로모 벤조산 유도체인 경우, 생성된 브로모 벤조산 아마이드 유도체와 아릴 보론산을 반응시키는 제 2단계를 더 포함하는 화학식 1 화합물의 제조방법.
- 제 5항에 있어서,상기 제 1단계는 N-하이드록시석신이미드 및 N,N'-다이사이클로헥실카르보다이이미드(DCC) 존재하에 반응시키는 화학식 1 화합물의 제조방법.
- 제 6항에 있어서,상기 제 2단계는 팔라듐촉매와 염기조건하에 반응시키는 화학식 1 화합물의 제조방법.
- 제 6항에 있어서,상기 아릴 보론산은 치환되지 않거나, 할로겐, C1 내지 C5 알킬, C1 내지 C5 알콕시, 메틸렌다이옥시 및 니트로기 중 하나 이상으로 치환된 아릴 보론산인 화학식 1 화합물의 제조방법.
- 유효성분으로서 제 1 항 내지 제 3 항 중 어느 한 항에 따른 화합물, 이의 이성질체, 이의 약학적으로 허용 가능한 염, 이의 프로드럭, 이의 수화물 또는 이의 용매화물을 포함하는 피부 미백용 조성물.
- 제 10 항에 있어서,조성물은 조성물 전체 중량을 기초로 제 1 항 내지 제 3 항 중 어느 한 항에 따른 화합물, 이의 이성질체, 이의 약학적으로 허용 가능한 염, 이의 프로드럭, 이의 수화물 또는 이의 용매화물을 0.01 중량% 내지 20 중량%로 포함하는 피부 미백용 조성물.
- 제 10 항에 있어서,상기 유효성분은 멜라닌 생성을 억제하는 피부 미백용 조성물.
- 제 10 항에 있어서,상기 유효성분은 타이로시나아제 활성을 억제하는 피부 미백용 조성물.
- 제 10 항에 있어서,조성물은 피부 외용제 조성물인 조성물.
- 제 10 항에 있어서,조성물은 화장료, 약학 또는 건강식품 조성물인 조성물.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16773425.0A EP3279184B1 (en) | 2015-03-31 | 2016-03-30 | Novel benzoic acid amide compound |
JP2017550926A JP6698100B2 (ja) | 2015-03-31 | 2016-03-30 | 新規な安息香酸アミド化合物 |
US15/561,585 US10385011B2 (en) | 2015-03-31 | 2016-03-30 | Benzoic acid amide compound |
CN201680031612.4A CN107667088B (zh) | 2015-03-31 | 2016-03-30 | 新型苯甲酸酰胺化合物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2015-0045201 | 2015-03-31 | ||
KR1020150045201A KR102395983B1 (ko) | 2015-03-31 | 2015-03-31 | 신규 벤조산 아마이드 화합물 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016159644A1 true WO2016159644A1 (ko) | 2016-10-06 |
Family
ID=57006110
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2016/003235 WO2016159644A1 (ko) | 2015-03-31 | 2016-03-30 | 신규 벤조산 아마이드 화합물 |
Country Status (6)
Country | Link |
---|---|
US (1) | US10385011B2 (ko) |
EP (1) | EP3279184B1 (ko) |
JP (1) | JP6698100B2 (ko) |
KR (1) | KR102395983B1 (ko) |
CN (1) | CN107667088B (ko) |
WO (1) | WO2016159644A1 (ko) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200085036A (ko) | 2019-01-04 | 2020-07-14 | (주)아모레퍼시픽 | 아다만탄 카르복실산 벤질 아마이드 유도체 화합물 및 그를 포함하는 피부 미백용 조성물 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08143525A (ja) * | 1994-11-21 | 1996-06-04 | Banyu Pharmaceut Co Ltd | ヒドロキシ安息香酸アミド誘導体を有効成分とする骨疾患の予防・治療剤 |
KR20020049340A (ko) * | 2000-12-19 | 2002-06-26 | 김선여 | 신규한 디페닐 아미드 유도체, 그의 제조방법 및 이를포함하는 약학 및 화장료 조성물 |
KR100680584B1 (ko) * | 2005-08-19 | 2007-02-08 | (주)아모레퍼시픽 | 히드록시벤즈아미드 화합물 및 그 제조방법, 및 이를유효성분으로 함유하는 화장료 조성물 |
KR20070046577A (ko) * | 2005-10-31 | 2007-05-03 | (주)아모레퍼시픽 | 젠티식산 유도체 화합물과 그 제조방법 및 이를 함유하는미백화장료 조성물 |
US20080214675A1 (en) * | 2004-08-27 | 2008-09-04 | Symrise Gmbh & Co. Kg | Hydroxybenzoic Acid Amides and the Use Thereof For Masking Bitter Taste |
KR20130015954A (ko) * | 2011-08-05 | 2013-02-14 | (주)아모레퍼시픽 | 신규 벤조산아미드 화합물 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100457949B1 (ko) | 2001-09-24 | 2004-11-18 | 주식회사 태평양 | 3,4,5-트리메톡시 페닐아세트산, 3,4,5-트리메톡시 신남산또는 3,4,5-트리메톡시 히드로 신남산의 에스테르화합물 및 이를 함유하는 미백 화장료조성물 |
KR100883870B1 (ko) | 2003-04-24 | 2009-02-17 | (주)아모레퍼시픽 | 3,4,5-트리메톡시 신남산 티몰 에스테르를 함유하는고분자 캡슐 및 이의 제조 방법, 및 이를 함유하는 화장료조성물 |
-
2015
- 2015-03-31 KR KR1020150045201A patent/KR102395983B1/ko active IP Right Grant
-
2016
- 2016-03-30 EP EP16773425.0A patent/EP3279184B1/en active Active
- 2016-03-30 CN CN201680031612.4A patent/CN107667088B/zh active Active
- 2016-03-30 US US15/561,585 patent/US10385011B2/en not_active Expired - Fee Related
- 2016-03-30 WO PCT/KR2016/003235 patent/WO2016159644A1/ko active Application Filing
- 2016-03-30 JP JP2017550926A patent/JP6698100B2/ja not_active Expired - Fee Related
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08143525A (ja) * | 1994-11-21 | 1996-06-04 | Banyu Pharmaceut Co Ltd | ヒドロキシ安息香酸アミド誘導体を有効成分とする骨疾患の予防・治療剤 |
KR20020049340A (ko) * | 2000-12-19 | 2002-06-26 | 김선여 | 신규한 디페닐 아미드 유도체, 그의 제조방법 및 이를포함하는 약학 및 화장료 조성물 |
US20080214675A1 (en) * | 2004-08-27 | 2008-09-04 | Symrise Gmbh & Co. Kg | Hydroxybenzoic Acid Amides and the Use Thereof For Masking Bitter Taste |
KR100680584B1 (ko) * | 2005-08-19 | 2007-02-08 | (주)아모레퍼시픽 | 히드록시벤즈아미드 화합물 및 그 제조방법, 및 이를유효성분으로 함유하는 화장료 조성물 |
KR20070046577A (ko) * | 2005-10-31 | 2007-05-03 | (주)아모레퍼시픽 | 젠티식산 유도체 화합물과 그 제조방법 및 이를 함유하는미백화장료 조성물 |
KR20130015954A (ko) * | 2011-08-05 | 2013-02-14 | (주)아모레퍼시픽 | 신규 벤조산아미드 화합물 |
Also Published As
Publication number | Publication date |
---|---|
US20180065922A1 (en) | 2018-03-08 |
JP2018511604A (ja) | 2018-04-26 |
CN107667088A (zh) | 2018-02-06 |
US10385011B2 (en) | 2019-08-20 |
KR102395983B1 (ko) | 2022-05-11 |
EP3279184A4 (en) | 2018-10-17 |
KR20160116861A (ko) | 2016-10-10 |
CN107667088B (zh) | 2020-04-24 |
JP6698100B2 (ja) | 2020-05-27 |
EP3279184A1 (en) | 2018-02-07 |
EP3279184B1 (en) | 2019-10-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2013022236A2 (ko) | 신규 벤조산아미드 화합물 | |
WO2014116022A1 (ko) | 레스베라트롤 유도체의 피부미백 용도 | |
WO2017222345A1 (en) | Novel autophagy activation-inducing compound for improving skin inflammation or aging | |
WO2015037891A1 (ko) | 신규 고리형 화합물을 함유하는 피부미백제 | |
WO2024049120A1 (ko) | 친환경 천연 공융 용매로 추출한 추출물을 포함하는 화장료 조성물 | |
WO2014084676A1 (ko) | 신규한 유사 세라마이드 화합물 및 그 제조방법 | |
WO2010123184A1 (ko) | 노르갈란타민 화합물을 유효성분으로 함유하는 탈모 질환의 예방 및 치료용 조성물 | |
WO2016159580A1 (ko) | 티아사포제놀 유도체를 유효성분으로 포함하는 조성물 | |
WO2014003232A1 (ko) | 황칠나무 추출물을 유효성분으로 포함하는 발모 촉진용 조성물 | |
WO2018062820A1 (ko) | 피토에스트로겐을 유효성분으로 포함하는 탈모방지 및 모발 성장 촉진용 조성물 | |
WO2016159640A2 (ko) | 5-아다만탄-1-일-n-(2,4-다이하이드록시벤질)-2,4-다이메톡시벤즈아마이드를 함유하는 항산화 또는 항노화 조성물 | |
WO2016159644A1 (ko) | 신규 벤조산 아마이드 화합물 | |
WO2020085826A1 (ko) | 육두구 추출물 또는 메이스리그난을 유효성분으로 함유하는 환경오염인자로부터 유도되는 피부자극 완화 및 피부보호용 조성물 | |
WO2017099531A1 (ko) | 신규 페놀산류 유도체 화합물, 및 이의 용도 | |
WO2016093515A1 (ko) | 장수 유전자 활성화용 조성물 | |
WO2023043197A1 (ko) | 신규한 카나비디올 유도체, 이의 제조방법 및 이를 포함하는 인지기능 개선용 조성물 | |
WO2019194583A1 (ko) | 3-페닐-2,8-디히드로피라노[2,3-f]크로멘 유도체 및 이를 포함하는 약학적 조성물 | |
WO2019231261A1 (ko) | 신규 바이페닐 유도체 화합물 및 이의 용도 | |
WO2022177313A1 (ko) | 세스퀴테르펜 유도체 또는 이의 약학적으로 허용가능한 염 및 이의 용도 | |
WO2017142368A2 (ko) | 알레르기성 또는 염증성 피부질환의 예방 또는 치료용 조성물 | |
WO2017057851A1 (ko) | 진세노사이드 지방산 에스터 화합물, 이의 제조방법 및 이를 포함하는 화장료 조성물 | |
WO2017014597A1 (ko) | 오미자 종자 추출물을 포함하는 피부 미백 개선용 화장품 조성물 | |
WO2022055045A1 (ko) | 콜라게나제 저해 활성 펩타이드 유도체 및 이의 용도 | |
WO2014092498A1 (ko) | 비타민 c와 비타민 b3의 컨쥬게이트 및 그를 포함하는 항산화제 | |
WO2019088648A1 (ko) | 미도드린을 포함하는 조성물 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16773425 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15561585 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2017550926 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2016773425 Country of ref document: EP |